atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.51 USD
-0.06 (-3.82%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.49 -0.02 (-1.32%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
atai Life Sciences N.V. [ATAI]
Reports for Purchase
Showing records 41 - 60 ( 64 total )
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Bicycle Day: Honoring the Chemist Who Opened the Door
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
4Q21 Results; Broad Progress; At Least 14 Drug Development and Enabling Technology Catalysts Expected in Next Two Years
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Conference Takeaways: Psychedelic Panel Discussion
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Biotechnology Breakthrough Innovation? Rubbish
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Psychedelic Medicine Panel Discussion at the Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Upbeat Cognitive Impairment in Schizophrenia KOL Event Highlights RL-007 Differentiation
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Psychedelic Medicine Companies are Building the Largest Pharmaceutical Market
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Lock-up Extended for OVER 30% of Shares Outstanding
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
RL-007 Improves Cognition & Biomarkers in Schizophrenia
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
RL-007 Clears Phase 2a Hurdle; Larger Phase 2 Trial Planned; KOL Event on January 18 Next Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
COMP360 TRD Data Validates atai Model; Multiple Potential Positive Events Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Psychedelics Space Poised for Breakout Year in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
And There Was One - Initiating Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department